Bill Ackman

John Gapper

We have been presented this week with two visions for the future of innovation in the pharmaceuticals industry. One is encouraging, the other is not.

John Gapper

The showdown between Bill Ackman and Dan Loeb, two activist fund managers, over the value of Herbalife, the US health supplement company, is entertaining for bystanders. It presages more such splits.

Traditionally, hedge funds have tended to hunt in packs – lining up to sell shares short or to arbitrage securities. One recent example was at JP Morgan Chase, where a set of hedge funds, led by Saba Capital, traded against the bank’s derivatives position.

In Herbalife’s case, Mr Ackman’s Pershing Square Capital and Mr Loeb’s Third Point, are arrayed against each other. Mr Ackman has accused Herbalife of being a Ponzi scheme, which it fiercely denies; Mr Loeb is on Herbalife’s sideRead more

Andrew Hill

I hope activist Bill Ackman knows what he’s getting into by backing the purchase of a 29 per cent stake in Burger King.

Mr Ackman is one of the founders of Justice Holdings, a UK investment vehicle that until Tuesday was, to me at least, as little-known as Burger King is famous. But Justice’s decision to buy a minority stake and take the company on to the New York Stock Exchange reminded me how, a few years ago, a rumour that Warren Buffett had his eye on the chain turned out to be a whopperRead more